JP2013506696A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013506696A5 JP2013506696A5 JP2012532388A JP2012532388A JP2013506696A5 JP 2013506696 A5 JP2013506696 A5 JP 2013506696A5 JP 2012532388 A JP2012532388 A JP 2012532388A JP 2012532388 A JP2012532388 A JP 2012532388A JP 2013506696 A5 JP2013506696 A5 JP 2013506696A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- medicament
- peptide
- heart failure
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 206010019280 Heart failures Diseases 0.000 claims 4
- 206010058222 Hypertensive cardiomyopathy Diseases 0.000 claims 3
- 230000000747 cardiac effect Effects 0.000 claims 3
- 230000002107 myocardial effect Effects 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 230000008828 contractile function Effects 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 241000208011 Digitalis Species 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 229940123457 Free radical scavenger Drugs 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 239000000150 Sympathomimetic Substances 0.000 claims 1
- 102000003938 Thromboxane Receptors Human genes 0.000 claims 1
- 108090000300 Thromboxane Receptors Proteins 0.000 claims 1
- 208000024799 Thyroid disease Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 206010000891 acute myocardial infarction Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 206010001584 alcohol abuse Diseases 0.000 claims 1
- 208000025746 alcohol use disease Diseases 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 239000004004 anti-anginal agent Substances 0.000 claims 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 claims 1
- 239000003416 antiarrhythmic agent Substances 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 239000002368 cardiac glycoside Substances 0.000 claims 1
- 229940097217 cardiac glycoside Drugs 0.000 claims 1
- 231100000457 cardiotoxic Toxicity 0.000 claims 1
- 230000001451 cardiotoxic effect Effects 0.000 claims 1
- 239000002327 cardiovascular agent Substances 0.000 claims 1
- 229940125692 cardiovascular agent Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000008602 contraction Effects 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 239000003527 fibrinolytic agent Substances 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 235000003642 hunger Nutrition 0.000 claims 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims 1
- 230000000297 inotrophic effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 claims 1
- 208000008494 pericarditis Diseases 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
- 239000002516 radical scavenger Substances 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
- 230000001624 sedative effect Effects 0.000 claims 1
- 230000037351 starvation Effects 0.000 claims 1
- 229930002534 steroid glycoside Natural products 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 229940127230 sympathomimetic drug Drugs 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 claims 1
- 229960000103 thrombolytic agent Drugs 0.000 claims 1
- 208000021510 thyroid gland disease Diseases 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 229940124549 vasodilator Drugs 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24868109P | 2009-10-05 | 2009-10-05 | |
| US61/248,681 | 2009-10-05 | ||
| US28948309P | 2009-12-23 | 2009-12-23 | |
| US61/289,483 | 2009-12-23 | ||
| PCT/US2010/051329 WO2011044044A1 (en) | 2009-10-05 | 2010-10-04 | Methods for the prevention or treatment of heart failure |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015050464A Division JP2015163609A (ja) | 2009-10-05 | 2015-03-13 | 心不全の予防又は処置の方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013506696A JP2013506696A (ja) | 2013-02-28 |
| JP2013506696A5 true JP2013506696A5 (enExample) | 2013-11-21 |
Family
ID=43823652
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012532388A Pending JP2013506696A (ja) | 2009-10-05 | 2010-10-04 | 心不全の予防又は処置の方法 |
| JP2015050464A Pending JP2015163609A (ja) | 2009-10-05 | 2015-03-13 | 心不全の予防又は処置の方法 |
| JP2016156631A Active JP6429835B2 (ja) | 2009-10-05 | 2016-08-09 | 心不全の予防又は処置の方法 |
| JP2018165223A Pending JP2018203764A (ja) | 2009-10-05 | 2018-09-04 | 心不全の予防又は処置の方法 |
| JP2020030241A Active JP7017762B2 (ja) | 2009-10-05 | 2020-02-26 | 心不全の予防又は処置の方法 |
| JP2022006917A Active JP7382607B2 (ja) | 2009-10-05 | 2022-01-20 | 心不全の予防又は処置の方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015050464A Pending JP2015163609A (ja) | 2009-10-05 | 2015-03-13 | 心不全の予防又は処置の方法 |
| JP2016156631A Active JP6429835B2 (ja) | 2009-10-05 | 2016-08-09 | 心不全の予防又は処置の方法 |
| JP2018165223A Pending JP2018203764A (ja) | 2009-10-05 | 2018-09-04 | 心不全の予防又は処置の方法 |
| JP2020030241A Active JP7017762B2 (ja) | 2009-10-05 | 2020-02-26 | 心不全の予防又は処置の方法 |
| JP2022006917A Active JP7382607B2 (ja) | 2009-10-05 | 2022-01-20 | 心不全の予防又は処置の方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (7) | US20110082084A1 (enExample) |
| EP (5) | EP3603658B1 (enExample) |
| JP (6) | JP2013506696A (enExample) |
| CN (2) | CN103845724A (enExample) |
| CA (1) | CA2776581C (enExample) |
| HK (1) | HK1217293A1 (enExample) |
| WO (1) | WO2011044044A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9306796B1 (en) | 2008-03-18 | 2016-04-05 | Mcafee, Inc. | System, method, and computer program product for dynamically configuring a virtual environment for identifying unwanted data |
| JP5909182B2 (ja) * | 2009-08-12 | 2016-04-26 | コーネル ユニヴァーシティー | 代謝性症候群を予防し又は治療するための方法 |
| EP3603658B1 (en) | 2009-10-05 | 2025-01-08 | Cornell University | Peptide for use in the treatment of heart failure resulting from hypertrophic cardiomyopathy |
| JP2013516426A (ja) * | 2009-12-31 | 2013-05-13 | ステルス ペプチドズ インターナショナル インコーポレイテッド | 冠状動脈バイパス移植術を行うための方法 |
| WO2013149172A1 (en) * | 2012-03-30 | 2013-10-03 | Stealth Peptides International, Inc. | Methods and compositions for the prevention and treatment neuropathy |
| MX2015005102A (es) * | 2012-10-22 | 2016-02-09 | Stealth Peptides Int Inc | Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociado con el mismo. |
| CA2916884C (en) | 2013-03-01 | 2021-02-09 | Stealth Biotherapeutics Corp | Methods for the treatment of mitochondrial disease |
| HUE046924T2 (hu) * | 2013-03-01 | 2020-03-30 | Stealth Biotherapeutics Corp | Módszerek és készítmények Barth szindróma megelõzésében vagy kezelésében történõ alkalmazásra |
| EP2996707B1 (en) * | 2013-05-14 | 2019-09-11 | Stealth Biotherapeutics Corp | Methods for the prevention or treatment of left ventricle remodeling |
| US20160095867A1 (en) * | 2013-05-28 | 2016-04-07 | Dana-Farber Cancer Institute, Inc. | Bet inhibition therapy for heart disease |
| US10047395B2 (en) * | 2013-06-26 | 2018-08-14 | Stealth Biotherapeutics Corp | Methods and compositions for detecting and diagnosing diseases and conditions |
| WO2015017861A1 (en) * | 2013-08-02 | 2015-02-05 | Stealth Peptides International, Inc. | Methods and compositions for the prevention and treatment of friedreich's ataxia |
| WO2016004441A1 (en) * | 2014-07-03 | 2016-01-07 | Stealth Peptides International, Inc. | Methods for the prevention or treatment of acute myocardial infarction injury |
| US10368774B2 (en) * | 2015-07-30 | 2019-08-06 | Medtronic, Inc. | Absolute intrathoracic impedance based scheme to stratify patients for risk of a heart failure event |
| CN116196389A (zh) * | 2016-01-06 | 2023-06-02 | 康德生物医疗有限公司 | 用于预防和治疗杜氏肌肉萎缩症的方法和组合物 |
| WO2017151886A1 (en) * | 2016-03-02 | 2017-09-08 | Stealth Biotherapeutics Corp | Methods and compositions for the treatment and prevention of pulmonary arterial hypertension |
| US10870678B2 (en) | 2016-04-11 | 2020-12-22 | Arcuate Therapeutics, Inc. | Chiral peptides |
| US11865162B2 (en) | 2016-07-01 | 2024-01-09 | Marshall University Research Corporation | Compositions and methods for treatment of uremic cardiomyopathy |
| WO2018195537A1 (en) | 2017-04-21 | 2018-10-25 | Northeast Ohio Medical University | Vasodilators for treatment of heart failure |
| DK3890765T3 (da) * | 2018-12-06 | 2023-10-23 | Stealth Biotherapeutics Inc | D-arg-2'6'-dmt-lys-phe-nh2 til anvendelse til behandling eller forebyggelse af sengers syndrom |
| CN112111003B (zh) * | 2019-06-20 | 2022-02-11 | 中国农业大学 | 含有me序列的一类新型抑制血小板聚集和抗血栓形成寡肽 |
| EP3771467A1 (en) | 2019-07-30 | 2021-02-03 | Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau | Ss-31 for the prevention and/or treatment of aneurysm |
| US20230256047A1 (en) * | 2020-06-17 | 2023-08-17 | Stealth Biotherapeutics Inc. | Methods and compositions for the treatment of muscular dystrophy |
| EP4210695A4 (en) | 2020-09-09 | 2025-04-16 | Social Profit Network | Methods and compositions for delivery of biotin to mitochondria |
| CN117881411A (zh) | 2021-06-01 | 2024-04-12 | 艾迪雅生物有限责任公司 | 用于眼部药物的延长释放药物递送系统和使用方法 |
| CN117384253A (zh) * | 2023-08-28 | 2024-01-12 | 南京医科大学 | 一类肽及其衍生物和应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4732898A (en) * | 1986-04-29 | 1988-03-22 | Warner-Lambert Company | 2-(2-aryl-2-oxoalkylidene) analogs of-3,5-pyridinedicarboxylic acid dialkyl esters useful for treatment of cardiovascular disorders |
| ES2085865T3 (es) * | 1988-06-30 | 1996-06-16 | Astra Ab | Analogos de dermorfina, sus metodos de preparacion, composiciones farmaceuticas, y metodos de tratamiento terapeutico que los emplean. |
| US5602100A (en) * | 1988-06-30 | 1997-02-11 | Astra Ab | Dermorphin analogs having pharmacological activity |
| US5652122A (en) * | 1989-12-21 | 1997-07-29 | Frankel; Alan | Nucleic acids encoding and methods of making tat-derived transport polypeptides |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5674534A (en) | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| DE69630918T2 (de) * | 1995-06-09 | 2004-10-28 | Hisamitsu Pharmaceutical Co., Inc., Tosu | Matrix für Iontophorese |
| US5849761A (en) * | 1995-09-12 | 1998-12-15 | Regents Of The University Of California | Peripherally active anti-hyperalgesic opiates |
| WO1997016169A1 (en) * | 1995-11-01 | 1997-05-09 | Chiron Corporation | Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space |
| US5885958A (en) * | 1997-03-25 | 1999-03-23 | Administrators Of The Tulane Educational Fund | Mu-opiate receptor peptides |
| US6489300B1 (en) * | 1997-07-31 | 2002-12-03 | Eugene D. Thorsett | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| AU1818299A (en) * | 1997-12-10 | 1999-06-28 | Washington University | Anti-pathogen system and methods of use thereof |
| US6268398B1 (en) * | 1998-04-24 | 2001-07-31 | Mitokor | Compounds and methods for treating mitochondria-associated diseases |
| US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
| SE9900961D0 (sv) * | 1999-03-16 | 1999-03-16 | Astra Ab | Novel compounds |
| CA2386239A1 (en) * | 1999-10-04 | 2001-04-12 | University Of Medicine And Dentistry Of New Jersey | Methods for identifying rna binding compounds |
| US6759520B1 (en) * | 1999-10-28 | 2004-07-06 | The New England Medical Center Hospitals, Inc. | Chimeric analgesic peptides |
| US20050192215A1 (en) * | 2000-01-21 | 2005-09-01 | Malabika Ghosh | Methods and materials relating to novel polypeptides and polynucleotides |
| AU2001277908A1 (en) * | 2000-07-18 | 2002-01-30 | Cornell Research Foundation Inc. | Medicinal uses of mu-opioid receptor agonists |
| US6900178B2 (en) | 2000-09-12 | 2005-05-31 | University Of Kentucky Research Foundation | Protection against ischemia and reperfusion injury |
| IT1318370B1 (it) * | 2000-12-21 | 2003-08-25 | Tonino Bombardini | Metodo e dispositivo per la diagnosi e la terapia dello scompensocardiaco cronico. |
| US20070015146A1 (en) * | 2001-05-22 | 2007-01-18 | Gene Logic, Inc. | Molecular nephrotoxicology modeling |
| WO2003029428A2 (en) * | 2001-10-01 | 2003-04-10 | Vanderbilt University | Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease |
| US7776925B2 (en) * | 2002-03-06 | 2010-08-17 | Duke University | Reversing, postponing or preventing the occurrence of GTN tolerance and/or generation of reactive oxygen species from mitochondria |
| PT1599216E (pt) | 2003-02-04 | 2013-12-17 | Cornell Res Foundation Inc | Métodos de prevenção da transição de permeabilidade mitocondrial |
| ZA200509229B (en) * | 2003-05-01 | 2007-03-28 | Cornell Res Foundation Inc | Method and carrier complexes for delivering molecules to cells |
| WO2005032481A2 (en) * | 2003-09-30 | 2005-04-14 | Scios Inc. | Quinazoline derivatives as medicaments |
| NZ549393A (en) * | 2004-01-23 | 2009-07-31 | Cornell Res Foundation Inc | Methods for reducing oxidative damage |
| US20050272101A1 (en) * | 2004-06-07 | 2005-12-08 | Prasad Devarajan | Method for the early detection of renal injury |
| KR20150013353A (ko) * | 2005-09-16 | 2015-02-04 | 코넬 리서치 화운데이션,인크. | Ｃｄ36 발현을 감소시키는 방법 |
| US20070259377A1 (en) * | 2005-10-11 | 2007-11-08 | Mickey Urdea | Diabetes-associated markers and methods of use thereof |
| US20080027082A1 (en) * | 2006-06-19 | 2008-01-31 | Berthold Hocher | Use of adenosine a1 antagonists in radiocontrast media induced nephropathy |
| EP2712620A1 (en) * | 2008-02-07 | 2014-04-02 | Cornell University | Methods for Preventing or Treating Insulin Resistance |
| WO2009108695A2 (en) | 2008-02-26 | 2009-09-03 | Cornell University | Methods for prevention and treatment of acute renal injury |
| CN102573881A (zh) | 2009-03-20 | 2012-07-11 | 通用医疗公司以马萨诸塞州通用医疗公司名义经营 | 预防和治疗烧伤损伤和继发性并发症的方法 |
| JP5909182B2 (ja) * | 2009-08-12 | 2016-04-26 | コーネル ユニヴァーシティー | 代謝性症候群を予防し又は治療するための方法 |
| EP3603658B1 (en) | 2009-10-05 | 2025-01-08 | Cornell University | Peptide for use in the treatment of heart failure resulting from hypertrophic cardiomyopathy |
| WO2011151359A1 (en) * | 2010-06-02 | 2011-12-08 | Noscira, S.A. | Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative |
-
2010
- 2010-10-04 EP EP19175034.8A patent/EP3603658B1/en active Active
- 2010-10-04 EP EP10822481.7A patent/EP2485749A4/en not_active Withdrawn
- 2010-10-04 CN CN201410049107.5A patent/CN103845724A/zh active Pending
- 2010-10-04 EP EP14151500.7A patent/EP2764871A1/en not_active Withdrawn
- 2010-10-04 JP JP2012532388A patent/JP2013506696A/ja active Pending
- 2010-10-04 US US12/897,325 patent/US20110082084A1/en not_active Abandoned
- 2010-10-04 WO PCT/US2010/051329 patent/WO2011044044A1/en not_active Ceased
- 2010-10-04 EP EP15154763.5A patent/EP2944317A1/en not_active Withdrawn
- 2010-10-04 CA CA2776581A patent/CA2776581C/en active Active
- 2010-10-04 CN CN2010800551907A patent/CN102711785A/zh active Pending
- 2010-10-04 EP EP16169795.8A patent/EP3120860B1/en active Active
-
2013
- 2013-09-24 US US14/035,577 patent/US20140100166A1/en not_active Abandoned
-
2015
- 2015-03-13 JP JP2015050464A patent/JP2015163609A/ja active Pending
- 2015-06-01 US US14/727,513 patent/US20160106800A1/en not_active Abandoned
-
2016
- 2016-05-10 HK HK16105288.2A patent/HK1217293A1/en unknown
- 2016-08-09 JP JP2016156631A patent/JP6429835B2/ja active Active
-
2017
- 2017-10-03 US US15/723,259 patent/US20180236025A1/en not_active Abandoned
-
2018
- 2018-09-04 JP JP2018165223A patent/JP2018203764A/ja active Pending
-
2020
- 2020-02-20 US US16/796,940 patent/US11534476B2/en active Active
- 2020-02-26 JP JP2020030241A patent/JP7017762B2/ja active Active
- 2020-10-29 US US17/084,046 patent/US20210187056A1/en not_active Abandoned
-
2022
- 2022-01-20 JP JP2022006917A patent/JP7382607B2/ja active Active
- 2022-12-12 US US18/079,604 patent/US12102659B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013506696A5 (enExample) | ||
| JP2022046811A5 (enExample) | ||
| Gradman et al. | Renin inhibition in hypertension | |
| RU2603050C2 (ru) | Способы и композиции для лечения гиперурикемии и метаболических нарушений, связанных с гиперурикемией | |
| WO2005087207A1 (en) | Compositions and methods for the treatment of depression and other affective disorders | |
| JP5425631B2 (ja) | ネコの全身性疾患の予防又は治療の為のアンジオテンシンｉｉ受容体アンタゴニスト | |
| ME00479B (me) | Lijek za profilaksu i tretman arterioskleroze i hipertenzije | |
| JP2014001234A (ja) | 糖尿病の合併症のための療法 | |
| JP2007119479A5 (enExample) | ||
| JP2006508056A5 (enExample) | ||
| JP2024533756A (ja) | アトゲパントを含む片頭痛の併用療法 | |
| JP2016522196A5 (enExample) | ||
| AU2020201980A1 (en) | Combination of FXR agonists | |
| EP4117659A1 (en) | Methods of treating respiratory disease with deupirfenidone | |
| TW201010695A (en) | Use of dronedarone for the preparation of a medicament for the prevention of stroke or transient ischemic attack | |
| WO2021195119A1 (en) | Methods of reducing the risk of, severity of, and treating coronavirus infections | |
| US20080153827A1 (en) | Method for the Treatment or Prevention of Cardiac Hypertrophy | |
| Zhu et al. | Efficacy and safety of telmisartan vs. losartan in control of mild‐to‐moderate hypertension: a multicentre, randomised, double‐blind study | |
| JPH11507012A (ja) | 心臓血管系病気の処置におけるアンギオテンシン変換酵素阻害薬と副作用軽減量のアルドステロン拮抗薬との組合わせ治療 | |
| US20240366596A1 (en) | Treatment of hfpef in post-menopausal women with an sgc stimulator | |
| Marques da Silva | Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan | |
| Geladari et al. | A case of influenza type a myocarditis that presents with ST elevation MI, cardiogenic shock, acute renal failure, and rhabdomyolysis and with rapid recovery after treatment with oseltamivir and intra-aortic balloon pump support | |
| Hamano et al. | Effects of low-dose sacubitril/valsartan on different stages of cardiac hypertrophy in salt-loaded hypertensive rats | |
| Oh et al. | Comparison of empagliflozin and sitagliptin therapy on myocardial perfusion reserve in diabetic patients with coronary artery disease | |
| MacMahon et al. | Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40–5967), a novel calcium antagonist |